Search

Author/Creator Shankar, Geetha

1. A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. (4th December 2017)

Authors:
Leong, Stephen; Moss, Rebecca A.; Bowles, Daniel W.; Ware, Joseph A.; Zhou, Jing; Spoerke, Jill M.; Lackner, Mark R.; Shankar, Geetha; Schutzman, Jennifer L.; van der Noll, Ruud; Voest, Emile E.; Schellens, Jan H.M.
Journal:
Oncologist
Issue:
Volume 22:Number 12(2017)
Page Start:
1491
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer. (November 2017)

Authors:
Soria, Jean-Charles; Adjei, Alex A.; Bahleda, Rastilav; Besse, Benjamin; Ferte, Charles; Planchard, David; Zhou, Jing; Ware, Joseph; Morrissey, Kari; Shankar, Geetha; Lin, Wei; Schutzman, Jennifer L.; Dy, Grace K.; Groen, Harry J.M.
Journal:
European journal of cancer
Issue:
Volume 86(2017)
Page Start:
186
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Issue 5 (May 2019)

Authors:
Reck, Martin; Mok, Tony S K; Nishio, Makoto; Jotte, Robert M; Cappuzzo, Federico; Orlandi, Francisco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A; Barlesi, Fabrice; Finley, Gene; Lee, Anthony; Coleman, Shelley; Deng, Yu; Kowanetz, Marc...
Journal:
Lancet
Issue:
Volume 7:Issue 5(2019)
Page Start:
387
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Issue 2 (21st February 2022)

Authors:
West, Howard Jack; McCleland, Mark; Cappuzzo, Federico; Reck, Martin; Mok, Tony SK; Jotte, Robert M; Nishio, Makoto; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha; Socinski, Mark A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗